Neil Martinson to Cost-Benefit Analysis
This is a "connection" page, showing publications Neil Martinson has written about Cost-Benefit Analysis.
Connection Strength
0,555
-
Intensified household contact tracing, prevention and treatment support versus enhanced standard of care for contacts of tuberculosis cases in South Africa: study protocol for a household cluster-randomised trial. BMC Infect Dis. 2019 Oct 12; 19(1):839.
Score: 0,147
-
A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care. 2016 10 01; 25(Sup10):S8-S17.
Score: 0,119
-
Evaluating the cost of adult voluntary medical male circumcision in a mixed (surgical and PrePex) site compared to a hypothetical PrePex-only site in South Africa. Glob Health Action. 2015; 8:29116.
Score: 0,113
-
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018 Dec 20; 19(1):693.
Score: 0,035
-
Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis. 2018 12 01; 22(12):1435-1442.
Score: 0,035
-
Improving active case finding for tuberculosis in South Africa: informing innovative implementation approaches in the context of the Kharitode trial through formative research. Health Res Policy Syst. 2017 May 30; 15(1):42.
Score: 0,031
-
The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis. 2013 Feb; 56(4):587-97.
Score: 0,023
-
The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):26-35.
Score: 0,020
-
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009 Aug 04; 151(3):157-66.
Score: 0,018
-
Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Clin Infect Dis. 2006 Jun 15; 42(12):1772-80.
Score: 0,015